Press Releases

Press Releases

Press releases

March 1, 2019
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRA™ (volanesorsen)

February 28, 2019
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome

February 26, 2019
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018

February 25, 2019
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

February 20, 2019
Akcea Therapeutics to Present at Upcoming Investor Conferences

February 13, 2019
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast

November 29, 2018
Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting

November 12, 2018
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

November 8, 2018
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions

November 6, 2018
Akcea Therapeutics to Present at Upcoming Investor Conferences

November 5, 2018
Akcea Reports Financial Results and Highlights for Third Quarter 2018

November 2, 2018
Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day

October 22, 2018
Akcea Therapeutics to Hold Third Quarter 2018 Financial Results Webcast

October 8, 2018
Akcea Announces Changes to Board of Directors

October 5, 2018
Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)

October 5, 2018
Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

October 4, 2018
Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada

September 24, 2018
Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

August 29, 2018
Akcea Therapeutics to Present at the Wells Fargo Healthcare Conference

August 27, 2018
Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA

August 6, 2018
Akcea Reports Financial Results and Highlights for Second Quarter 2018

August 2, 2018
Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America

July 31, 2018
Akcea Announces Publication of Study Results Showing Multiple Benefits of Patient-to-Patient Connectivity in FCS

July 23, 2018
Akcea Therapeutics to Hold Second Quarter 2018 Financial Results Webcast

July 11, 2018
Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union

July 5, 2018
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

June 13, 2018
Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

June 12, 2018
Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis

June 5, 2018
Akcea Therapeutics Appoints Industry Leader Dr. Richard Moscicki to Board of Directors

June 1, 2018
Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI

May 29, 2018
Akcea Therapeutics to Present at the Jefferies Global Healthcare Conference

May 10, 2018
FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome

May 3, 2018
Akcea Reports Financial Results and Highlights for First Quarter 2018

May 2, 2018
Akcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCS

April 26, 2018
Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions

April 24, 2018
Akcea Therapeutics to Hold First Quarter 2018 Financial Results Webcast

April 21, 2018
Akcea Therapeutics to Present Data on Inotersen for the Treatment of hATTR Amyloidosis at the 2018 American Academy of Neurology Annual Meeting

April 17, 2018
Sarah Boyce Joins Akcea Therapeutics as President and Member of the Board of Directors

April 17, 2018
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR

March 26, 2018
Akcea Convenes First FCS Global Connection Summit

March 26, 2018
Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis

March 21, 2018
MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)

March 15, 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR

March 12, 2018
Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo

March 6, 2018
Akcea Therapeutics to Present at Upcoming Investor Conferences

February 28, 2018
Akcea Therapeutics Recognizes Rare Disease Day by Spotlighting Several Historic “Firsts” for People Living with Familial Chylomicronemia Syndrome

February 27, 2018
Akcea Therapeutics Canada Announces the Launch of FCS Focus Education & Support Program

February 26, 2018
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017

February 15, 2018
Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome

February 12, 2018
Akcea Therapeutics to Hold Fourth Quarter 2017 Financial Results Webcast

February 7, 2018
Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx

January 5, 2018
Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease

December 14, 2017
Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)

December 7, 2017
Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

November 15, 2017
Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS

November 13, 2017
Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias

November 7, 2017
Akcea to Present at Stifel 2017 Healthcare Conference

November 6, 2017
Akcea Reports Financial Results and Highlights for Third Quarter 2017

October 31, 2017
Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx

October 27, 2017
Akcea Therapeutics Named Among Top 100 Women-Led Businesses in Massachusetts for Second Consecutive Year

October 23, 2017
Akcea Therapeutics to Hold Third Quarter 2017 Financial Results Webcast

October 16, 2017
Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome

October 10, 2017
Akcea Therapeutics’ Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS)

October 4, 2017
Akcea Therapeutics Canada Appoints Nelly Komari, B. Pharm., MSc. as Medical Director

September 12, 2017
Akcea Announces Filing of New Drug Submission for Volanesorsen to Health Canada

September 12, 2017
Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada

September 6, 2017
Akcea Therapeutics Establishes Canadian Subsidiary

Supporting patients

Discover the ways in which Akcea Canada supports patients and Healthcare Professionals alike.

Inside Akcea

Learn about the Akcea mindset.